In biotech, traders investing on margin have targeted small-cap clinical stage firms. While April 2024 FDA approvals boosted several names, missed trial endpoints in others triggered margin-related sell-offs within 48 hours. This semiconductor company is poised to keep growing as Intel struggles with a key part of its business. The market is walking a tightrope between an AI boom and an economic slowdown. Oil price retracements from $92 to $84/barrel compressed gains, forcing stop-outs in leveraged crude-related equities. Experienced traders advise scaling in with smaller margin allocations during commodity swings.